Equities research analysts at Guggenheim started coverage on shares of Metsera (NASDAQ:MTSR – Get Free Report) in a report issued on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $56.00 price target on the stock. Guggenheim’s target price points to a potential upside of 87.86% from the company’s previous close.
A number of other equities research analysts also recently weighed in on the company. Evercore ISI started coverage on Metsera in a research report on Tuesday. They set an “outperform” rating on the stock. Bank of America began coverage on shares of Metsera in a report on Tuesday. They issued a “buy” rating and a $38.00 price target on the stock.
Check Out Our Latest Analysis on MTSR
Metsera Stock Down 5.8 %
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
- Five stocks we like better than Metsera
- The Most Important Warren Buffett Stock for Investors: His Own
- Confluent: How Data Streaming May Transform AI
- How Investors Can Find the Best Cheap Dividend Stocks
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- What to Know About Investing in Penny Stocks
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
